Immuno Oncology Assays Market Size, Share and Industry Analysis Report, Regional Outlook, Growth Potential, Competitive Market Share & Forecast, 2024 – 2032
Report ID: GMI3697
Download Free PDF
Authors:
Monali Tayade,
Immuno Oncology Assays Market Size
Immuno Oncology Assays Market size is expected to witness commendable growth over 2024-2032, driven by the benefits of cancer immunotherapy over chemotherapy and other conventional therapies, including fewer immediate and long-term side effects like heart problems and peripheral neuropathy.
The World Health Organization predicts a staggering 77% increase in new cancer cases by 2050, reaching over 35 million, up from approximately 20 million in 2022. Cancer remains a leading cause of morbidity and mortality globally, driving the demand for innovative diagnostic and therapeutic solutions. Immuno-oncology assays play a crucial role in characterizing tumor-immune interactions, predicting patient responses to immunotherapy, and guiding personalized treatment approaches. With the growing burden of cancer across diverse cancer types, the demand for immuno-oncology assays is expected to escalate significantly.
Immuno Oncology Assays Market Trends
Technological advancements in assay development are further driving innovation in the immuno-oncology assays market. Improved assay sensitivity, specificity, and multiplexing capabilities enable comprehensive profiling of immune responses and tumor microenvironments. Next-generation sequencing (NGS), flow cytometry, and multiplex immunohistochemistry (IHC) techniques are increasingly utilized to analyze complex immune landscapes and identify predictive biomarkers for immunotherapy response.
Immuno Oncology Assays Market Analysis
The consumables segment size is anticipated to expand through 2032, credited to the significant rise in R&D investments and initiatives undertaken by key market players to develop advanced techniques. These innovations are utilized in diagnostic tests in clinical labs and hospitals, providing efficient and fast results.
The colorectal cancer indication segment will account for a major share in the market by 2032, attributed to the growing number of geriatric people globally. According to the WHO, the population aged 60 years and above will surge from 1 billion in 2020 to over 1.4 billion in 2030, which could drive segmental growth, as most people diagnosed with colorectal cancer are above 50 years of age. Likewise, the rising adoption of sedentary lifestyles and the global burden of obesity will augment the need for immuno oncology treatments for colorectal cancer, as obesity is a well-established factor of the cancer type.
North America immuno oncology assays market is set to amass considerable gains by 2032, on account of the increasing prevalence of cancer and the significant development of combination immunotherapy for patients diagnosed with metastatic kidney cancer in the U.S. Dual immunotherapies, including ipilimumab/nivolumab, for example, have become a new standard for kidney cancer care across the country. Additionally, advanced healthcare infrastructure, alongside the awareness about benefits of early disease detection.
Immuno Oncology Assays Market Share
Key immuno oncology assays industry players include:
Strategic product launches and business expansions are among the initiatives undertaken by these firms to boost their footprint in the global industry.
Immuno Oncology Assays Industry News
Research methodology, data sources & validation process
This report draws on a structured research process built around direct industry conversations, proprietary modelling, and rigorous cross-validation and not just desk research.
Our 6-step research process
1. Research design & analyst oversight
At GMI, our research methodology is built on a foundation of human expertise, rigorous validation, and complete transparency. Every insight, trend analysis, and forecast in our reports is developed by experienced analysts who understand the nuances of your market.
Our approach integrates extensive primary research through direct engagement with industry participants and experts, complemented by comprehensive secondary research from verified global sources. We apply quantified impact analysis to deliver dependable forecasts, while maintaining complete traceability from original data sources to final insights.
2. Primary research
Primary research forms the backbone of our methodology, contributing nearly 80% to overall insights. It involves direct engagement with industry participants to ensure accuracy and depth in analysis. Our structured interview program covers regional and global markets, with inputs from C-suite executives, directors, and subject matter experts. These interactions provide strategic, operational, and technical perspectives, enabling well-rounded insights and reliable market forecasts.
3. Data mining & market analysis
Data mining is a key part of our research process, contributing nearly 20% to the overall methodology. It involves analysing market structure, identifying industry trends, and assessing macroeconomic factors through revenue share analysis of major players. Relevant data is collected from both paid and unpaid sources to build a reliable database. This information is then integrated to support primary research and market sizing, with validation from key stakeholders such as distributors, manufacturers, and associations.
4. Market sizing
Our market sizing is built on a bottom-up approach, starting with company revenue data gathered directly through primary interviews, alongside production volume figures from manufacturers and installation or deployment statistics. These inputs are then pieced together across regional markets to arrive at a global estimate that stays grounded in actual industry activity.
5. Forecast model & key assumptions
Every forecast includes explicit documentation of:
✓ Key growth drivers and their assumed impact
✓ Restraining factors and mitigation scenarios
✓ Regulatory assumptions and policy change risk
✓ Technology adoption curve parameter
✓ Macroeconomic assumptions (GDP growth, inflation, currency)
✓ Competitive dynamics and market entry/exit expectations
6. Validation & quality assurance
The final stages involve human validation, where domain experts manually review filtered data to identify nuances and contextual errors that automated systems might miss. This expert review adds a critical layer of quality assurance, ensuring data aligns with research objectives and domain-specific standards.
Our triple-layer validation process ensures maximum data reliability:
✓ Statistical Validation
✓ Expert Validation
✓ Market Reality Check
Trust & credibility
Verified data sources
Trade publications
Security & defense sector journals and trade press
Industry databases
Proprietary and third-party market databases
Regulatory filings
Government procurement records and policy documents
Academic research
University studies and specialist institution reports
Company reports
Annual reports, investor presentations, and filings
Expert interviews
C-suite, procurement leads, and technical specialists
GMI archive
13,000+ published studies across 30+ industry verticals
Trade data
Import/export volumes, HS codes, and customs records
Parameters studied & evaluated
Every data point in this report is validated through primary interviews, true bottom-up modelling, and rigorous cross-checks. Read about our research process →